This research group aims to uncover the mechanisms and molecular pathways driving cancer cell programs and progression using cutting-edge genomic technologies and with a primary focus on colorectal cancer. Its research also extends to other cancer types and genetic diseases.

The team’s current interests lie in the development of technical and bioinformatic tools that facilitate the processing and interpretation of genomic and epigenomic data, bridging the gap between next-generation technologies and clinical applications. To this end, they have created web applications and tools that make it easier to manage and access genomic data. For the study of colorectal tumorigenesis and cell differentiation processes they use human samples and in vitro models to create reference frameworks and working models for understanding the mechanisms behind malignant transformation.

The research group has also developed novel methods to interrogate genetic and epigenetic information, and established a spin-off company to translate these advances in genomic and epigenomic technologies into clinical practice. Finally, the group has developed a technique to pinpoint the epigenetic state of the "dark genome" with the aim of understanding the functional properties of specific repeat elements and how they contribute to genome regulation colon cancer cells.

Keywords: Colorectal cancer, epigenetics, biomarker, integrative molecular profiling, tumour progression.

Group Leader

  • Miguel Ángel Peinado

    Miguel Ángel Peinado

    Miguel A. Peinado has a degree in Biology (Univiversity of Barcelona) and a long track of research at Hospital Clínic (Master’s thesis, 1985-1986), Hospital de Sant Pau (PhD, 1986-1989), California Inst. Biol. Res (postdoc, 1990), IRO (reincorporation contract, 1992) and as a principal investigator at IRO (1992-2005), IDIBELL (2005-2007), IMPPC (2007-2015) and IGTP (2016-). He has also had management responsibilities as Department director at IRO, Scientific coordinator at IMPPC and Deputy Director at IGTP. Currently, Peinado is codirector of the Cancer Research Translational Program (CARE) of IGTP.

    MA Peinado has participated in more than 25 research projects and has published >140 research articles, including leading multidisciplinary journals such as Nature, Science, NEJM and PNAS, and specialised journals in the fields of Genetics (Nat Genet, Nucl Acids Res, Genome Res, etc) and Cancer (JNCI, Cancer Res, J Clin Oncol, Cancer Cell, etc.). MA Peinado has also led research contracts with industry and is coinventor of five patents. Since 2015, he is CSO of Aniling, a start-up company dedicated to accelerating the transfer of Epigenetics advances to Medicine through the development of NGS technologies.

    Contact: mpeinado(ELIMINAR)

Research lines

The main focus of this research group is the characterisation of the molecular mechanisms underlying cell programs and the identification of molecular markers with clinical application. The specific topics currently being developed in the lab include:

  • Epigenetic landmarks for cancer patient stratification
  • Drivers of genome reprogramming in cancer
  • New targets and tools for early diagnosis and treatment
  • The role of dark DNA in genome regulation

Active projects

Enabling personalized colorectal cancer management by coupling unified genetic and epigenetic testing to organoid-based treatment screening (Spot & Hit)

PI: L. Coll
Funding agency: Ministerio de Ciencia e Innovación (MCINN)
Agency code: CPP2021-008602
Duration: 2022 - 2025

Proyecto CPP2021-008602 financiado por:

Proyecto CPP2021-008602 financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

Integration of specific and interspersed genetic and epigenetic signals as a multi-tool to type colorectal cancer (GEALUS)

PI: MA Peinado
Funding agency: Ministerio de Ciencia e Innovación (MCINN)
Agency code: PID2021-124315OB-I00
Duration: 2022 - 2025

Past projects

DEEP-GEUS: a new Artificial Intelligence assisted integrative genomic diagnostics system of Chronic Lymphocytic Leukemia

Funding agency: Centro para el Desarrollo Tecnológico Industrial (CDTI)
Agency code: IDI-20191104
Duration: 2019 - 2023

Germline predisposition to serrated polyposis syndrome: functional charaterization of candidate genes by CRISPR-CAS and organoid modeling

PI: S. Castellví
Funding agency: Fundació Marató de TV3
Agency code: 2019 2020008
Duration: 2021 - 2023

Use of artificial intelligence and systems biology for diagnosis and personalized risk assessment for inherited kidney diseases, focusing on Alport Syndrome

PIs: R Torra, MA Peinado, A Ortiz, M Vallverdú
Funding agency: Fundació Marató de TV3
Agency code: 22/C/2020
Duration: 2021 - 2023

Scientific publications

Matas J, Kohrn B, Fredrickson J, Carter K, Yu M, Wang T, Gui X, Soussi T, Moreno V, Grady WM, Peinado MA, Risques RA. Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. Cancer Res. 2022 Apr 15;82(8):1492-1502. DOI: 10.1158/0008-5472.CAN-21-3607. PMID: 35425963; PMCID: PMC9022358.


View publications, Peinado MA on PubMed

A complete list of publications by the group members will soon be available on this page.


- Research, Projects

Researcher Sofía España receives a €140,000 grant from the Spanish Association Against Cancer

Dr Sofía España, a researcher from the Cancer Mechanisms and Pathways Group at IGTP and the Badalona Applied Research Group in Oncology (B·ARGO) IGTP-Institut Català d'Oncologia (ICO), has been awarded one of the prestigious Clínico Junior Grants by the Spanish Association Against Cancer. This grant will enable her to balance her clinical duties with research, focusing on the development of a minimally invasive diagnostic tool to classify different types of colorectal cancer, advancing towards precision medicine.

- Campus Can Ruti

The IGTP presents CARE Translational Program in Cancer Research

CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.

+ News